Kurnit et al. [71] evaluated the molecular expression in presumably low-risk endometrial cancer and found that in stage I or II, the presence of either Tp53 mutations or CTNNB1 mutations represented a risk factor for disease recurrence in otherwise presumed low-risk patients [71]. Here, TP53 is linked to endometrial cancer.